- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04159142
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
This is a multi-center , open-lable clinical trial. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have <1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. TNBC is diagnosed in 15-20% of breast cancer cases and tends to occur in younger women and have biologically more aggressive high grade disease.
The purpose of this study is to assess the efficacy and safety of the following two combinations: i) nab-paclitaxel+carboplatin; ii) nab-paclitaxel+capecitabine in subjects with advanced TNBC and up to one prior line of systemic treatment for metastatic disease. Maintenance therapy with capecitabine after completion of combination chemotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050011
- Recruiting
- The Fourth Hospital of Hebei Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Females with age between 18 to 70 years old;
- Histologically confirmed triple negative breast cancer;
- No more than one-line prior treatment for locally advanced or metastatic breast cancer;
- Have at least one measurable lesion as per the RECIST criteria (version 1.1);
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to one;
- Patients with life expectancy of at least 3 months;
- Bone marrow function:neutrophils (≥1.5×10^9/L), platelets (≥100×10^9/L), hemoglobin (≥90 g/L);
- Renal and hepatic function: Serum creatinine≤ 1.5×institutional upper limit of normal (ULN); AST and ALT ≤ 2.5 × ULN; Total bilirubin≤1.5×ULN, or patients with Gilbert's syndrome ≤ 2.5 × ULN;
- Patients had good compliance with the planned treatment, understood the research process and written informed consent.
Exclusion Criteria:
- Patients with heart disease above grade II (including grade II) identified by New York Heart Association (NYHA) scores;
- Brain metastasis;
- Recurrence or metastasis within 6 months after capecitabine withdrawal;
- Recurrence or metastasis within 6 months after platinum withdrawal;
- Progression in the treatment, recurrence or metastasis of paclitaxel (including albumin paclitaxel) within 6 months;
- Patients required clinical intervention with gastrointestinal bleeding, gastrointestinal obstruction and non-feeding;
- Patients who had Grade 2 or above Peripheral neuropathy;
- Patients with severe systemic infection or other serious diseases;
- Patients allergic to or intolerant of chemotherapeutic drugs or their adjuvants;
- Patients with other malignant tumors in the past five years, except for cured cervical carcinoma in situ and non-melanoma skin cancer;
- Pregnancy or lactation, as well as reproductive age patients who refused to take appropriate contraceptive measures in the trial;
- Participation in any trial drug treatment or another interventional clinical trial 30 days before first dose was given;
- The researchers considered the patients who were not suitable for enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Nab-paclitaxel + Carboplatin
Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles; Maintenance therapy: Capecitabine 1000 mg/m^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;
|
nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
|
EXPERIMENTAL: Nab-paclitaxel + Capecitabine
Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and capecitabine given IV at 1000 mg/m^2 bid, d1-14 every 21 days x 6 cycles; Maintenance therapy: Capecitabine 1000 mg/m^2 bid, d1-14; every 21 days, until disease progression or intolerable toxicity;
|
Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and capecitabine given IV at 1000 mg/m^2 bid, d1-14 every 21 days x 6 cycles;
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: 3 years
|
Up to disease progression or death due to any cause
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS rate for 6 cycles
Time Frame: At the end of Cycle 6 (each cycle is 21 days)
|
From the date of randomization to the end of 6 cycles
|
At the end of Cycle 6 (each cycle is 21 days)
|
Objective response rate (ORR)
Time Frame: 3 years
|
To evaluate the Overall Response Rate of patients with advanced triple-negative breast cancer
|
3 years
|
Overall survival (OS)
Time Frame: 3 years
|
To evaluate the overall survival of patients with advanced triple-negative breast cancer
|
3 years
|
Adverse events (AE)
Time Frame: 3 years
|
To evaluate the adverse events of patients with advanced triple-negative breast cancer
|
3 years
|
Collaborators and Investigators
Investigators
- Study Chair: Zefei Jiang, M.D., Beijing 302 Hospital
- Study Chair: Cuizhi Geng, M.D., The Fourth Hospital of Hebei Medical University
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Triple Negative Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Carboplatin
- Paclitaxel
- Capecitabine
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- CSPC-KAL-BC-16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triple Negative Breast Cancer
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Melinda TelliPfizer; BioMarin PharmaceuticalCompletedAdvanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast CancerUnited States
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
UNICANCERSOLTI Breast Cancer Research Group; Vall d'Hebron Institute of Oncology; MSD...Not yet recruitingTriple-negative Breast Cancer
-
Shanghai Jiao Tong University School of MedicineCSPC Ouyi Pharmaceutical Co., Ltd.; Innovent Biologics, Inc.Not yet recruiting
Clinical Trials on Nab-paclitaxel + Carboplatin
-
Shengjing HospitalRecruiting
-
Shengjing HospitalRecruitingBreast Cancer | Immunotherapy | Stereotactic RadiotherapyChina
-
Women's Hospital School Of Medicine Zhejiang UniversitySun Yat-sen University; Qilu Hospital of Shandong University; Second Affiliated... and other collaboratorsRecruitingEpithelial Ovarian Carcinoma Stage III | Epithelial Ovarian Carcinoma Stage IV | Fallopian Tube Carcinoma Stage III | Fallopian Tube Carcinoma Stage IV | Primary Peritoneal Carcinoma Stage III | Primary Peritoneal Carcinoma Stage IVChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingInflammatory Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor NegativeUnited States
-
Hebei Medical University Fourth HospitalBeijing 302 Hospital; CSPC Ouyi Pharmaceutical Co., Ltd.UnknownBreast Cancer | Triple-negative Breast Cancer | Nab-paclitaxelChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangdong Provincial People's Hospital; Third Affiliated Hospital, Sun Yat-Sen...RecruitingLung Cancer, Non-small Cell | Artificial IntelligenceChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingSalivary Gland Tumors | Salivary Gland Malignant NeoplasmsChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingSalivary Gland Tumors | Salivary Gland Malignant NeoplasmsChina
-
Shanghai Henlius BiotechActive, not recruitingSquamous Non Small Cell Lung CancerChina, Turkey, United States, Georgia, Poland, Russian Federation, Ukraine
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingOropharyngeal Squamous Cell Carcinoma | Oral Squamous Cell Carcinoma | Oral Cavity Squamous Cell CarcinomaChina